Payment overview · 2025
General Payments
$502.36
15 reported records · 10 companies
Healthcare provider profile · identity verified
Mark A Reedy, MD
Allopathic & Osteopathic Physicians|Family Medicine · MUNCIE, IN · NPI 1508944596
Verified facts
What the public records show
CMS Open Payments records show Mark A Reedy, MD received $502.36 in general payments during 2025 across 15 reported records.
Vanda Pharmaceuticals Inc. accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $115.20 | 22.9% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $114.60 | 22.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.52 | 10.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.93 | 9.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.63 | 9.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.78 | 8.9% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.06 | 5.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 3.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.57 | 3.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.22 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $483.51 | 14 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $115.20 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $114.60 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $49.93 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $44.78 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.78 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.82 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 179 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
90 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
103 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
179 | 43 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 933 | 257 |
| Amlodipine Besylate | Amlodipine Besylate | 790 | 202 |
| Levothyroxine Sodium | Levothyroxine Sodium | 613 | 154 |
| Lisinopril | Lisinopril | 502 | 142 |
| Metoprolol Succinate | Metoprolol Succinate | 413 | 124 |
| Hydrochlorothiazide | Hydrochlorothiazide | 312 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 301 | 97 |
| Metformin Hcl | Metformin Hcl | 292 | 88 |
| Omeprazole | Omeprazole | 259 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 229 | 71 |
| Duloxetine Hcl | Duloxetine Hcl | 212 | 51 |
| Losartan Potassium | Losartan Potassium | 207 | 56 |
| Furosemide | Furosemide | 206 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 205 | 55 |
| Gabapentin | Gabapentin | 203 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 203 | 59 |
| Alendronate Sodium | Alendronate Sodium | 183 | 52 |
| Carvedilol | Carvedilol | 182 | 48 |
| Potassium Chloride | Potassium Chloride | 182 | 51 |
| Eliquis | Apixaban | 179 | 43 |
| Metformin Hcl Er | Metformin Hcl | 179 | 48 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 158 | 43 |
| Allopurinol | Allopurinol | 153 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 144 | 33 |
| Sertraline Hcl | Sertraline Hcl | 132 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 39 |
| Synthroid | Levothyroxine Sodium | 108 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 33 |
| Warfarin Sodium | Warfarin Sodium | 107 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 31 |
| Ozempic | Semaglutide | 103 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 102 | 82 |
| Simvastatin | Simvastatin | 101 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 25 |
| Montelukast Sodium | Montelukast Sodium | 98 | 28 |
| Valsartan | Valsartan | 95 | 23 |
| Farxiga | Dapagliflozin Propanediol | 90 | 24 |
| Ezetimibe | Ezetimibe | 89 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 23 |
| Trulicity | Dulaglutide | 87 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 79 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 40 |
| Tramadol Hcl | Tramadol Hcl | 77 | 19 |
| Glimepiride | Glimepiride | 73 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 14 |
| Prednisone | Prednisone | 73 | 58 |
| Mirtazapine | Mirtazapine | 71 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 36 |
| Benazepril Hcl | Benazepril Hcl | 64 | 18 |
| Donepezil Hcl | Donepezil Hcl | 63 | 19 |
| Januvia | Sitagliptin Phosphate | 60 | 13 |
| Atenolol | Atenolol | 59 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 59 | 49 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 59 | 44 |
| Jardiance | Empagliflozin | 56 | 15 |
| Memantine Hcl | Memantine Hcl | 54 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 52 | 14 |
| Famotidine | Famotidine | 52 | 15 |
| Tradjenta | Linagliptin | 51 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 13 |
| Trazodone Hcl | Trazodone Hcl | 50 | 13 |
| Meloxicam | Meloxicam | 48 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 48 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 47 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 45 | 33 |
| Methylprednisolone | Methylprednisolone | 45 | 36 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 11 |
| Torsemide | Torsemide | 43 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 41 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 41 | suppressed |
| Alprazolam | Alprazolam | 38 | suppressed |
| Cephalexin | Cephalexin | 38 | 34 |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 31 |
| Irbesartan | Irbesartan | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Estradiol | Estradiol | 29 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 29 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 21 |
| Spironolactone | Spironolactone | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 24 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nystatin | Nystatin | 18 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 11 |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $502.36 · 15 records | Vanda Pharmaceuticals Inc. | AIRSUPRA, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, FANAPT, GARDASIL 9, JARDIANCE, NURTEC ODT, PROQUAD, SAPIEN 3 Ultra RESILIA, The Cologuard Plus Collection Kit, VAXELIS, VAXNEUVANCE, VENASEAL, WATCHMAN FLX, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error